Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Ho | - |
dc.contributor.author | Song, Gwan Gyu | - |
dc.date.accessioned | 2023-02-06T03:40:03Z | - |
dc.date.available | 2023-02-06T03:40:03Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 0340-1855 | - |
dc.identifier.issn | 1435-1250 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/62338 | - |
dc.description.abstract | Objective This study compared the relative efficacy and safety of olokizumab, tocilizumab, and sarilumab in rheumatoid arthritis (RA) patients who were intolerant or responding inadequately to methotrexate (MTX). Methods We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of olokizumab, tocilizumab, and sarilumab in RA patients who were intolerant or responding inadequately to MTX. Results Six RCTs comprising 4439 patients met the inclusion criteria. Tocilizumab, sarilumab, olokizumab, and adalimumab treatments achieved a significant American College of Rheumatology 20% (ACR20) response rate compared with placebo. However, tocilizumab was associated with the most favorable surface area using the cumulative ranking curve (SUCRA) for the ACR20 response rate. The ranking probability based on the SUCRA indicated that tocilizumab treatment had the highest probability of providing the best ACR20 response rate, followed by sarilumab, olokizumab every 2 weeks (Q2W), olokizumab Q4W, adalimumab 40 mg, and placebo. The ACR50 and 70 response rates showed a distribution pattern similar to that of the ACR20 response rate. However, olokizumab Q4W had a higher ranking probability than olokizumab Q2W. The SUCRA rating showed that the placebo was the best intervention with the least adverse events (AEs) and withdrawal due to AEs, followed by interleukin‑6 inhibitors. Conclusion Tocilizumab, sarilumab, and olokizumab are more effective than adalimumab and have similar efficacy and safety in RA patients with inadequate responses to MTX. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Dr. Dietrich Steinkopff Verlag | - |
dc.title | Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.publisher.location | 독일 | - |
dc.identifier.doi | 10.1007/s00393-022-01315-0 | - |
dc.identifier.scopusid | 2-s2.0-85145703907 | - |
dc.identifier.wosid | 000909946500002 | - |
dc.identifier.bibliographicCitation | Zeitschrift für Rheumatologie | - |
dc.citation.title | Zeitschrift für Rheumatologie | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | INTERLEUKIN-6 RECEPTOR INHIBITION | - |
dc.subject.keywordPlus | MODIFYING ANTIRHEUMATIC DRUGS | - |
dc.subject.keywordPlus | HUMAN MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | INADEQUATE RESPONSE | - |
dc.subject.keywordPlus | DISEASE-ACTIVITY | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | INCONSISTENCY | - |
dc.subject.keywordPlus | POLYMORPHISMS | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordAuthor | Tocilizumab | - |
dc.subject.keywordAuthor | Sarilumab | - |
dc.subject.keywordAuthor | Olokizumab | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.subject.keywordAuthor | Network meta-analysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.